AI For Pharma Growth

Digital biomarkers are turning everyday movement into clinically useful data, giving doctors a clearer picture of what’s happening between appointments, and giving pharma new ways to measure drug impact earlier and more precisely. In this episode, Dr Andree Bates interviews Dr Quique Llaudet, CEO and co-founder of Ephion Health, about precision monitoring and how AI-driven mobility analysis is changing both clinical care and drug development.Quique shares his journey from academic research into entrepreneurship, driven by a desire to turn science into real products that help patients. Ephion Health grew out of early work with paediatric hospitals in Barcelona, where sensor technology used in rehabilitation and exoskeleton projects revealed a bigger opportunity: objective, high-sensitivity gait and movement analysis that can detect disease signatures and track progression over time.The conversation breaks down what a digital biomarker actually is: a measurable signal of health captured via connected devices and analysed with digital methods. Ephion’s platform integrates multiple validated, off-the-shelf sensors to capture rich movement data in a short test, replacing blunt measures like the six-minute walk test with something both more sensitive and less stressful for patients. The system then combines key parameters into a single composite score to track progression and treatment response.Quique also tackles the “black box” concern head on. He explains how their models are developed alongside clinicians, with clinical relevance checked throughout, and how doctors can inspect the underlying parameters behind the biomarker score in a dashboard. For rare diseases with limited data, he highlights deep collaboration with clinicians and patient associations, and the use of synthetic data to support modelling and testing.Finally, Quique outlines the economics: reducing specialist assessment time, enabling more frequent remote monitoring, supporting earlier treatment adjustments, and helping pharma generate evidence in real-world settings. The long-term vision is continuous monitoring that helps clinicians act earlier, plus AI-assisted diagnosis and eventually prevention.Topics CoveredWhat digital biomarkers are and how they differ from traditional biomarkersTurning mobility data into clinically meaningful signalsMulti-sensor monitoring: IMUs, pressure insoles, and EMGWhy short tests can beat the six-minute walk testComposite biomarker scoring and tracking treatment responseAI patterns clinicians may sense but cannot quantifyExplainability and building models “hand in hand” with doctorsData challenges in rare disease and the role of patient associationsSynthetic data for modelling and validationEconomic impact: time savings, remote monitoring, and better treatment adjustmentPharma use cases: real-world evidence and earlier efficacy signals in trialsAbout the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

Digital twins have become one of the most promising tools in Alzheimer’s research, but the bigger story is what happens when they scale across disease areas. In this episode, Dr Andree Bates interviews Aaron Smith, Founder and Head of Machine Learning at Unlearn AI, about how “digital twin generators” can transform trial design by modelling realistic patient progression and improving statistical power without compromising the fundamentals of randomised controlled trials.Aaron shares his journey from academic mathematics into computer vision and machine learning, then into biopharma, where Unlearn began by building generative models that learn the joint distribution of clinical variables. In practice, that means the model can take baseline patient measurements and generate likely future progressions that are as indistinguishable from real clinical records as possible.The conversation dives into a key misconception: digital twins are not only about replacing control arms. Aaron explains a regulatory friendly approach where you keep standard trial structure, but add counterfactual information for every patient into the analysis. Unlearn’s best known method, ProCOVA (prognostic covariate adjustment), summarises a predicted control outcome per patient and uses it for covariate adjustment, creating more efficient treatment effect estimates. The headline result is simple: you can increase power, or reduce recruitment burden while maintaining power, potentially speeding time to results.Finally, Aaron explains why scaling across diseases is genuinely hard. Data structures differ wildly by indication, missingness can block transfer learning, and areas like oncology require modelling complex treatment histories. He also highlights that combining sources is not just “more data”, it demands careful harmonisation and context modelling to avoid biased predictions, especially when bringing in real world evidence.Topics CoveredWhat “digital twin generators” are in clinical trialsGenerative modelling of clinical records and disease progressionCounterfactual prediction under standard of careWhy replacing control arms is not the only use caseProCOVA and prognostic covariate adjustmentGetting more statistical power and reducing trial sizeFDA openness to digital twins in trials and what it enablesWhy scaling across disease areas is not just parameter tuningMissing data, confounding context, and data harmonisationCNS versus oncology modelling challengesReal world evidence and how to validate digital twin modelsAbout the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.Vitalay shares his background across biotech and pharma, including work in biomarker discovery, translational medicine, and data science, and how frustration with existing approaches led her to build a new architecture for clinical genomic insights. A core theme is that traditional methods often oversimplify biology by forcing outcomes into binary labels and treating each disease area as an isolated box, even when the available data is too limited to answer meaningful questions well.The conversation explores how foundation model approaches can unify clinical, genomic, transcriptomic, proteomic and imaging signals to create a fuller “biological fingerprint” of each patient. Vitalay explains how this can enable earlier insight from single-arm trials by effectively benchmarking against standard-of-care cohorts, helping teams enrich later-stage trials with the right subpopulations sooner, and reducing time and cost.They also discuss the real blockers to adoption: not only scientific conservatism, but commercial uncertainty around how Big Pharma structures deals with tech-bio companies that bring platforms rather than single assets. Vitalay argues that explainability is non-negotiable in this space, because clinicians, scientists, patients, and regulators will not trust black-box predictions.Topics CoveredWhy AI is shifting from failure prevention to pipeline redesignBiomarker discovery beyond binary responder vs non-responder labelsBreaking disease silos to learn across indicationsMultimodal integration: DNA, RNA, protein, imaging, and clinical dataUsing foundation models to bridge trial data and real-world dataPatient stratification and trial enrichment from early studiesReverse translation and identifying unmet need before target huntingExplainability, trust, and regulatory readinessAdoption barriers: culture, champions, and deal structures for tech-bioMisconceptions about AI in drug development and why “press a button” is a mythAbout the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

Enterprise AI is shifting from experiments to infrastructure, and that changes everything. In this episode, Dr Andree Bates interviews Jocelyn Houle, Senior Director of Product Management at Securiti.ai, to explore the future of enterprise AI, agents, automation, and the single biggest blocker to scale: trust.Jocelyn shares what she is seeing across highly regulated industries as organisations move beyond proof of concept into production. She explains why the agent era raises the stakes: when you add LLMs into workflows, systems become non-deterministic and harder to trace end to end. In her words, once the data goes in, you cannot easily untangle it, so organisations need stronger controls around permissions, auditing, and policy enforcement.A major theme is that data foundations matter more than ever. Jocelyn warns that agents will not magically repair messy data, they will expose weak data quality immediately. From there, she outlines how trust can be won or lost at the prompt layer, both outbound (what the model says to customers) and inbound (what users share with the organisation). She also discusses “toxic combinations”, where overlapping access can accidentally leak sensitive information, plus the growing need for prompt screening and tracking to reduce risk.The conversation also digs into explainability and auditability, with Jocelyn being refreshingly honest that the perfect solution is not here yet. Instead, enterprises are using practical approaches like benchmarking releases side by side, cataloguing AI agents in use, and building governance that is starting to look more like modern cybersecurity: baked in from the start, not added as an afterthought.Jocelyn closes with clear advice for leaders: start “left” with raw data controls, build a truly cross-functional team, and begin setting up auditability even with imperfect tools, because regulators are catching up and they will expect responsible behaviour.Topics CoveredWhere enterprise AI adoption really stands todayWhat makes AI agents different from traditional automationNon-determinism, traceability, and why permissions matterData mapping, policy controls, and reducing sensitive data leakagePrompt security: outbound and inbound trust risks“Toxic combinations” and exposure through agent workflowsExplainability, benchmarking, and parallel release testingAI governance becoming as essential as cybersecurityTop 3 pieces of advice for CTOs starting their AI journeyWhy enterprise AI will become so embedded we stop talking about itAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | XAbout the Podcast

Clinical trials are a massive industry with brutal economics, long timelines, and failure rates that would be unacceptable in almost any other sector. In this episode, Dr Andree Bates is joined by Dr Joseph Geraci of NetraMark to break down why trials fail so often, how patient heterogeneity drives cost and uncertainty, and where AI can realistically shift the economics.Joseph shares his unusual path from mathematics and mathematical physics into oncology and medical science, including a decision to move into hospital research rather than follow a more traditional academic route. That shift shaped his focus: not just discovering more molecules, but understanding why the same drug can work brilliantly for some patients and fail for others.A central theme is that clinical trials are not “one disease, one patient type”. In many areas, disease definitions are too broad for trial design, making trials feel like trying to hit multiple dartboards with one dart. Joseph explains how NetraMark’s approach aims to identify meaningful subpopulations inside small datasets, finding the “pocket” where a drug’s true advantage shows up, without discarding patients as outliers.The conversation also touches on regulators, including growing interest in innovation pathways, but also the fear pharma teams have about changing protocols and risking setbacks. Joseph argues that AI’s biggest economic value in trials is speed, using better insight from limited trial data to guide enrichment strategies, smarter substudy decisions, and faster iteration, especially in oncology and rare disease where time is everything.Topics CoveredWhy clinical trial economics are becoming unsustainablePatient heterogeneity and why disease definitions break trialsFinding “pockets” of responders within small datasetsTrial enrichment and substudies that reveal a drug’s advantageWhy pharma adoption can be slow, even when failures are constantRegulatory interest, guidelines, and sponsor risk aversionLarge language models vs mathematically augmented AI approachesSpeed as the biggest economic lever in trialsPractical examples across depression, schizophrenia, oncology, and beyondWhat clinical trials could look like in five years with AI-driven insightThis show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more. Dr. Andree Bates LinkedIn | Facebook | X

AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “broken before they even begin” and what a real AI strategic blueprint needs to include if you want adoption, scale, and outcomes, not just impressive pilots.Dr Andree explains the core paradox: AI can now synthesise literature at speed, accelerate discovery, and outperform human experts in specific tasks, but the business results are often disappointing because the failure is rarely technical. It is strategic. She describes the “technical obsession trap”, where organisations spend months optimising models and benchmarking competitors while adoption remains low and teams are not operationally ready to act on the outputs.She outlines three common failure modes:Innovation Theatre, where disconnected pilots never compound into enterprise valueCompetitor benchmarking, where companies copy use cases that do not fit their contextTechnology first strategy, where tools are bought before priorities are definedFrom there, she maps what a strong pharma AI blueprint must cover: grounding in business objectives, end to end deployment architecture (data, governance, capability, change), leadership and culture, rigorous financial modelling tied to revenue and ROI, and alignment across functions including commercial, medical, regulatory, R&D, market access, insights, and tech teams.Dr Andree closes with a clear challenge for leadership: competitive advantage will come to organisations that build the most intelligent operating model around AI, not those with the biggest budgets. She also offers a 45 minute AI strategic diagnostic for pharma and biotech leaders who want an honest read on what to fix before investing further.Topics CoveredWhy pharma AI impact often disappoints despite powerful toolsThe “technical obsession trap” and the AI strategy blind spotInnovation Theatre, competitor benchmarking, and technology first mistakesWhat a pharma AI strategic blueprint must includeGovernance as a foundation for scale and regulatory trustLeadership, culture, and adoption as the real differentiatorsFinancial modelling and prioritisation based on ROI and revenue impactOrganisational alignment across the full pharma value chainChoosing the right advisory partner and avoiding generic frameworksWhy strategy must come before technology to build durable advantageAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

Healthcare accessibility is still being held hostage by phone queues, missed calls, and clunky portals. In this episode, Dr Andree Bates sits down with Josh Taylor of TxtSquad to explore why simple, secure texting can remove friction for patients and providers, and how AI can support the conversation without making care feel robotic.Josh explains why SMS works where apps often fail: it is familiar, low effort, and asynchronous. That means patients can reply on their own time, while care teams can manage conversations in a way that fits real clinic workflows instead of forcing everyone into yet another platform.They dig into the pharma and adherence angle too. Josh shares how two-way messaging helps teams move beyond generic reminders and uncover the real reasons people stop taking medication, opening the door to earlier support, smarter interventions, and better outcomes.Finally, Josh outlines where AI adds value inside messaging: triage for common questions, translation, summarisation, and staff copilots. He also highlights the importance of compliance, clear boundaries, and human oversight when dealing with sensitive health information. The future, he suggests, is smarter communication across SMS, voice, and phone-based assistants, designed to meet patients where they already are.Topics CoveredWhy portals and apps struggle with adoption in healthcareSMS as a low-barrier, asynchronous engagement channelBuilding a two-way patient to provider communication loopMedication adherence: understanding drop-off, not just sending remindersPatient assistance programmes and support at scaleClinical trial recruitment and retention using messagingAI in messaging: triage, translation, summarisation, and staff copilotsCompliance considerations and handling sensitive informationWhat comes next: voice agents and deeper integration with phone workflowsAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating businessDr. Andree Bates LinkedIn | Facebook | X

As artificial intelligence becomes increasingly woven into everyday life, the real question isn’t just what AI can do — it’s what it should do for humans. In this episode, Dr Andree Bates interviews Dr Morteza Zihayat of Heisenberg Network to explore Human-Centred AI: designing intelligent systems that prioritise welfare, autonomy, dignity and trust over pure technical capability.Morteza explains how his background in data mining led to a key insight: numbers can be incredibly powerful, but they still “miss the mark” when human values are ignored. That perspective shaped his work in Human-Centred AI and helped inspire Heisenberg Network, a decentralised infrastructure designed to transform fragmented, messy data into high-quality, AI-ready intelligence — in minutes rather than weeks — while dramatically reducing cost.The conversation digs into what human-centred design looks like in practice. Morteza introduces a “ladder of priorities” to manage conflicting values — from safety and laws at the top, through ethics and platform policies, down to individual preferences — and argues that making this ladder public gives people a right to debate and appeal decisions when something feels wrong.Finally, Morteza tackles the unavoidable trade-offs between performance and fairness, sharing a real example from mental health research where reducing model accuracy produced a fairer system that clinicians felt more comfortable using. His key message is urgent: powerful AI is coming either way — making it human-centred is a choice we need to commit to now, with transparency becoming non-negotiable.Topics CoveredWhat Human-Centred AI means in practiceTurning user stories into concrete design checksThe “ladder of priorities” for managing conflicting valuesDesigning systems for welfare, autonomy, dignity and trustPower caps and keeping AI controllablePersonalisation vs wellbeing (and avoiding filter bubbles)Where bias enters: data, models, and feedback loopsDebiasing pipelines and fairness as real-world data shiftsLearning from users without storing raw personal dataExplainability challenges with reasoning modelsWhy transparency is becoming non-negotiableWhen less accuracy can be the more responsible choiceAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business.Dr. Andree Bates LinkedIn | Facebook | X

Designing proteins that have never existed in nature is no longer sci-fi — it’s becoming a real drug discovery strategy. In this episode, Kashif Sadiq, Founder & CEO of DenovAI Biotech, explains how AI is powering a shift from searching for biologic binders to intentionally designing new proteins from scratch.Kashif shares his journey from studying physics at University of Cambridge into computational biophysics, and how breakthroughs like AlphaFold from DeepMind helped unlock the next frontier: de novo protein design. Instead of hoping evolution has already produced a usable molecule, Kashif describes how modern AI can engineer bespoke proteins for specific functions, including challenging targets where traditional approaches come up short.The conversation dives into the sheer scale of “protein space” and why evolution has only explored a tiny fraction of what’s possible. Kashif outlines how this opens the door to targeting diseases and biological mechanisms that have historically been considered undruggable, especially where flat protein interfaces or complex signalling pathways have made small molecules ineffective.Finally, Kashif explains why combining generative AI with physics-based methods is essential to reduce false positives, improve real-world binding performance, and enable “one-shot design” — where discovery and optimisation become a single integrated process. He also shares what keeps him up at night: clinical trial attrition — and why designing better earlier may be the key to improving success later.Topics CoveredDe novo protein design vs traditional biologics discoveryWhy evolution explored only a tiny fraction of protein space“Programmable biologics” and intentional molecular designAlpha Design and designing proteins from the inverse problemAntibodies, nanobodies, and therapeutic protein engineeringCombining generative AI with physics-based validationReducing false positives in protein binding predictions“One-shot design” and compressing discovery timelinesUndruggable targets, flat interfaces, and intracellular signallingClinical trial attrition and what’s missing at the preclinical stageWhen the first de novo-designed therapeutic could enter trialsAbout the PodcastAI for Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical, no-fluff conversations that demystify AI for biopharma execs — from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, market access, medical affairs, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

Large Language Models (LLMs) are moving far beyond text generation—and into the heart of scientific discovery and pharmaceutical research. In this episode, Javier Tordable, founder and CEO of Pauling.ai and former Google technologist, explains how agentic AI systems are transforming early-stage drug discovery.Javier shares how modern LLMs differ from earlier generations, highlighting their ability to perform autonomous, multi-step scientific workflows rather than isolated tasks. These AI agents can read and synthesize massive volumes of scientific literature, generate novel hypotheses, validate ideas against published research, and accelerate computational chemistry simulations that once took months or years.The discussion dives into how LLMs are being used today to identify drug targets, design molecules, optimize clinical trials, and reduce manual scientific labor, while still preserving the critical role of human creativity and experimental validation. Javier also addresses the real risks—hallucinations, data quality, reproducibility—and why hybrid AI + physics-based approaches are essential for trustworthy results.This episode is a must-listen for researchers, founders, and operators exploring LLMs in biotech, pharma AI, scientific automation, and computational drug discovery.Topics CoveredLarge Language Models (LLMs) in science and pharmaAI agents and autonomous research workflowsEarly-stage drug discovery accelerationComputational chemistry and molecular simulationsAI-assisted literature review and hypothesis generationClinical trial optimization with AIReducing R&D timelines and operational bottlenecksRisks, hallucinations, and validation in scientific AIAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.Dr. Andree Bates LinkedIn | Facebook | Twitter

Artificial intelligence is rapidly reshaping the pharmaceutical industry—and nowhere is that more evident than in small-molecule drug discovery. In this episode, we sit down with Tom Shani, CEO and co-founder of ProPhet, an AI-driven biotech company focused on discovering drugs for hard-to-target proteins.Tom explains how machine learning models, transformers, and AI-driven molecular representations are overcoming the biggest limitations of traditional drug discovery: slow timelines, high failure rates, missing data, and billion-dollar R&D costs. Rather than relying solely on physics-based simulations and trial-and-error lab work, AI systems learn patterns directly from noisy biological data—making them uniquely suited for real-world biology.The conversation explores how AI can compress drug discovery timelines from decades to years, reduce failed trials, and dramatically lower costs by improving early-stage target and molecule selection. Tom also breaks down why small molecules remain the backbone of modern medicine, how AI enables scalable exploration of vast chemical space, and why trust, regulation, and validation remain the biggest hurdles to adoption.This episode is essential listening for anyone working in pharma R&D, biotech, AI-driven drug discovery, computational biology, or life sciences innovation.Topics CoveredAI-powered small-molecule drug discoveryMachine learning vs traditional pharmaceutical R&DHard-to-drug proteins and undruggable targetsTransformers, AlphaFold, and molecular representationsReducing drug discovery timelines and costsAI robustness to missing and noisy biological dataOff-target effects, toxicity, and safety predictionThe future of AI in pharma and biotech startupsAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry.Dr. Andre Bates shares a pragmatic view on AI in the biopharma industry, cutting through the hype to explore where AI is already delivering value and where companies need to focus for real impact. From regulatory document preparation to AI-driven drug discovery, Andre explains how AI is transforming the industry—and why human adoption is just as critical as the technology itself.What You’ll Learn from This Episode:The “low-hanging fruit” for AI in pharma, including regulatory, clinical, and medical affairs applications.How AI is accelerating drug discovery, clinical trials, and predictive healthcare.The importance of human trust and adoption in successful AI implementation.Predictions for AI-driven transformations in business models, digital twins, and disease prevention.Practical steps for building a disciplined AI strategy with measurable ROI.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry.Dr. Bates shares actionable insights into the real-world potential of AI to reduce time-to-market, cut development costs, and create competitive advantage. From AI strategy alignment with business goals to executive board responsibilities and data governance, this episode dives deep into what it takes to implement AI successfully across the pharmaceutical value chain.What You’ll Learn in This Episode:How AI can accelerate drug discovery and clinical trials, potentially reducing costs and time-to-market by up to 50–60%.Why many pharma companies are struggling to convert AI pilots into measurable business outcomes.The importance of connecting AI initiatives to strategic business objectives, rather than treating them as isolated tech projects.Key roles for the CEO, CFO, R&D leaders, and board directors in driving enterprise-wide AI adoption.How to identify "pockets of excellence" in AI implementation and the path to fully integrated AI in pharma.Practical guidance on leveraging company data for AI while avoiding common pitfalls.Emerging trends like digital twins, synthetic data, and multimodal AI for the life sciences sector.Whether you’re a pharma executive, AI strategist, or R&D professional, this episode provides a comprehensive roadmap to harness AI for sustainable innovation and measurable ROI in biopharma.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simon for a deep dive into how AI is transforming the biopharma industry. With over two decades of experience applying AI across R&D, clinical development, regulatory, medical affairs, and commercial teams, Dr. Bates explains how the field has evolved from early digitisation to the current generative AI era.She discusses the post-ChatGPT shift in executive decision-making, why many organisations are stuck in endless piloting, and how companies can build a strategic, business-aligned AI roadmap that delivers real-world value. Dr. Bates also breaks down a practical framework for calculating ROI on AI initiatives and highlights where pharma teams are seeing the strongest impact today—from drug discovery and clinical trials to regulatory workflows and personalised commercial engagement.What You’ll Learn From This EpisodeHow AI has evolved in biopharma over the past two decades.Why ChatGPT created a turning point for pharma executives.Common pitfalls that cause AI pilots to fail—and how to avoid them.How to build a strategic, outcome-driven AI roadmap.A practical framework for calculating ROI on AI initiatives.Where AI delivers the highest ROI across the pharma value chain.How AI can elevate—not replace—the expertise of scientific, clinical, and medical teams.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, we take you inside the AI factory — the place where companies are transforming real business operations using AI workflows, not just experimenting with flashy demos or proofs of concept.AI strategist Dustin Jensen breaks down what differentiates AI systems that scale from those that become expensive experiments. He explains why companies waste money when they “throw AI at a workflow” without truly understanding the process, the data, and the human-in-the-loop requirements.You’ll hear how to build AI workflows that integrate with existing infrastructure, collaborate with people, and close the loop on real tasks — not copilots that need constant oversight.What You’ll Learn:What an AI factory actually is and how it worksHow to turn AI pilots into production-grade systemsThe role of workflow discovery and data flow mappingWhy most AI deployments fail due to poor data quality and lack of readinessHow to design systems where humans and AI collaborate seamlesslyThe mindset shift employees need when adopting generative AI toolsThe difference between copilots and AI agents that close the loop on tasksHow to build AI with safety, reliability, and error-handling designed inWhy small, specialized agents outperform “monolithic” do-everything modelsAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

In today’s episode, we explore the Simplify to Scale approach — how companies can use AI, intelligent automation, and design thinking to remove operational friction, improve workflows, and unlock sustainable growth. Our guest, Anthony Franco, is a serial entrepreneur, AI strategist, and co-author of AI First Principles and The Wiser Method. He has launched and successfully exited six companies, and now advises enterprise leaders on how to operationalize AI safely and strategically.You'll learn how to identify the difference between necessary complexity (the kind that creates competitive advantage) and unnecessary complexity (the kind that wastes time, budget, and energy). Anthony also reveals why most companies fail with AI implementation — and how the right simplification process prevents wasted effort.If you're a founder, CEO, COO, or operator who wants to grow without adding more tools, processes, or people, this episode shows how to scale smarter, not bigger.What You’ll LearnThe Simplify to Scale methodologyHow to combine AI + design thinking to streamline operationsWhy complexity can be a competitive differentiatorThe #1 mistake companies make when implementing AIHow to identify process friction and hidden inefficienciesWhy AI won’t take jobs — but will eliminate monotonous workHow to build human-in-the-loop systems (AI + people working together)Metrics to track success: cycle time, velocity, exceptions, cost reductionAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

What if drug testing didn’t need animals — or risky early-stage human trials?In today’s episode, we explore organ-on-a-chip technology, a breakthrough innovation that is transforming how drugs are developed, tested, and brought to market. These micro-sized devices — containing real living human cells — can accurately replicate the function of organs like the liver, lungs, brain, kidney, and intestine.Our guest, Daniel Levner, Chief Technology Officer and co-founder of Emulate, breaks down how this technology works, why the FDA is recognizing it as an alternative to animal testing, and how it’s already being used by leading pharma companies to predict toxicity, reduce failures in clinical trials, and accelerate drug development.What You’ll Learn in This EpisodeWhy 90% of new drugs fail in clinical trials — and how organ chips solve that problem.How living human cells inside microfluidic channels behave like real organs.Why organ-on-a-chip is more accurate than traditional cell cultures and animal testing.How pharma companies like Moderna are already using organ chips to avoid costly primate testing.How linking multiple organ chips could create “a human-on-a-chip” system.The impact on rare disease research, CRISPR-based disease modeling, and personalized medicine.How organ chips could save the pharma industry $3B+ annually and lower drug costs for patients.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, we explore one of the most disruptive advancements currently reshaping the pharmaceutical and biotech industry: AI-powered digital twins for clinical trials.Our guest, Aaron Smith, PhD — Founder and Head of Machine Learning at Unlearn.AI — breaks down how digital twins and generative AI are transforming drug development by enabling faster, smaller, and more efficient clinical trials.Unlearn.AI builds digital twin models: virtual patient replicas created using clinical trial data, registry data, and real-world data. These digital twins allow researchers to simulate how a patient’s disease will progress under standard care, long before a clinical trial is completed. When combined with randomized controlled trials, this technology reduces data variability, increases trial power, and can dramatically shrink sample sizes and timelines.Some pharma companies are already estimating a six-month reduction in time-to-market, with millions saved in development and operational costs.What You’ll LearnWhat digital twins are and how they simulate patient outcomes using real-world clinical data.How AI is enabling smaller Phase III trials without sacrificing statistical power.Why digital twins are helping pharma identify which patients are most likely to benefit from specific treatments.The biggest barriers to adopting AI in drug development (hint: it’s not the regulators — it’s culture).Trends shaping the future of clinical trials and precision medicine over the next 10 years.Digital twins reduce variability and increase power by predicting how each patient would progress under standard care.The approach (called Prognostic Covariate Adjustment / ProCova) can be used in traditional randomized controlled trials.Pharma partners expect significant reductions in trial timelines and costs.AI enables precision trial design by identifying the most prognostic patient features and outcome measures.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

What if artificial intelligence could detect throat cancer instantly — in real time — during a routine exam?In this groundbreaking episode, we speak with Marius Wellenstein, Founder and CEO of WSK Medical, the company behind the world’s first AI-powered endoscopic solution for real-time detection and classification of throat and head & neck cancers.Marius shares how his team developed a plug-and-play AI system that integrates seamlessly into existing endoscopy equipment to identify both benign and malignant lesions within seconds — helping ENT surgeons catch cancers earlier, reduce diagnostic delays, and save lives.He also discusses how AI is redefining clinical workflows, accelerating cancer diagnostics, and bringing expert-level accuracy to every outpatient clinic, no matter its size.If you’re interested in the future of AI in medicine, oncology innovation, or digital health entrepreneurship, this episode is a must-listen.Key HighlightsHow Marius identified the gap between AI innovation and real-world clinical useThe technology behind AI-powered laryngoscopy and how it works in real timeTraining the model on over 80,000 medical images and 1,000+ patient casesHow AI can cut cancer diagnosis from weeks to same-day resultsWhy WSK Medical’s plug-and-play AI can fit any ENT or endoscopy setupLessons in bringing AI innovation into conservative healthcare systemsThe life-saving potential of early cancer detection through accessible AI toolsWhat’s next for WSK Medical — expanding from throat cancer to other cancer typesAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, we sit down with Dr. William Ho, President, CEO, and Co-Founder of IN8 Bio — a pioneering biotech company developing next-generation Gamma Delta T cell therapies for both solid and hematologic cancers.From Wall Street to the biotech lab, Dr. Ho shares his remarkable journey and how he’s leveraging artificial intelligence, data analytics, and computational biology to reshape cell therapy development, manufacturing, and scalability.Discover how AI is transforming every stage of biotech — from drug discovery and clinical trial optimization to manufacturing automation and investor relations — and why Dr. Ho believes it’s key to achieving IN8 Bio’s mission of Cancer Zero.Key HighlightsFrom finance to pharma: How Dr. Ho’s Wall Street experience shaped his approach to building a public biotech company.AI in biotech innovation: Real-world examples of using natural language processing and machine learning to uncover drug-development gaps.Data-driven discovery: How IN8 Bio uses AI, RNA Seq, and single-cell analysis to advance Gamma Delta T cell therapies.Smarter manufacturing: The role of AI and LLMs in optimizing cell-therapy production, reducing costs, and managing global supply chains.Regulatory readiness: How biotech companies can navigate FDA compliance while integrating AI tools.Capital markets & biotech: Why the next generation of investors discover biotech companies on TikTok — and how IN8 Bio adapts to the algorithmic market.Mission Cancer Zero: How AI will help achieve a future where no patient dies of cancer.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter